

A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or **Clinically-Defined FCS at High Risk of Acute Pancreatitis** Gerald F. Watts, D.Sc., M.D., Ph.D.¹, Robert S. Rosenson, M.D.², Robert A. Hegele, M.D.⁴, Antonio Gallo, M.D., Ph. D.⁵, Ann Mertens, M.D., Ph.D.⁶, Alexis Baass, M.D., M.Sc.⁷, Rong Zhou, Ph.D.⁸, Ma'an Muhsin, M.D.⁸, Jennifer Hellawell, M.D.⁹, Daniel Gaudet, M.D., Ph.D.¹⁰, on behalf of the PALISADE Study Group*


¹School of Medicine, University of Western Australia and Department of Cardiology, Royal Perth Hospital, Perth, Australia (G.F.W.); ²Metabolism and Lipids Program, Mount Sinai, New York, NY, USA (R.S.R.); ³Robarts Research Institute, London, Ontario, Canada (R.A.H.); ⁴NYU School of Medicine, NYU Langone Health, New York City, NY, USA (I.J.G); ⁵Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Endocrinology, University Hospitals Leuven – KU Leuven, Belgium (A.M.); ⁷Department of Medicine, McGill University and Genetic Dyslipidemia Clinic, Montréal Clinical Research Institute (IRCM), Montréal, Québec, Canada (A.B.); ⁸Stanford University, Palo Alto, CA, USA (N.J.L.); ¹⁰Université de Montréal and ECOGENE-21, Montréal, Québec, Canada (D.G). *Full listing of PÁLISADE Study Group available at: Watts GF, et al. N Engl J Med. 2024. DOI: 10.1056/NEJMoa2409368. Supplement. Online ahead of print.

BACKGROUND

Persistent Chylomicronemia


- Is reflected by extremely high plasma triglycerides (> 880 mg/dL) caused by impaired circulatory clearance of chylomicrons containing TGs derived from the diet¹
- Due to ultrarare bi-allelic recessive variants of lipoprotein lipase (LPL; Familial Chylomicronemia Syndrome, FCS) or more common genetic variants (Multifactorial Chylomicronemia Syndrome) that impair triglyceride lipolysis¹⁻⁴
- Adults with extreme chylomicronemia can phenocopy classical FCS
- Chylomicronemia causes multiple symptoms (physical, cognitive, emotional), the most severe being acute pancreatitis and its life-threatening sequelae⁵⁻⁸
- Directly related to triglyceride levels (> 500 mg/dL)
- Current therapeutic agents (fibrates, n-3 fatty acids, statins, niacin) are generally ineffective

Plozasiran: An Investigational SiRNA Therapeutic Targeting APOC3, a Key **Regulator of TG and TRL Metabolism**



METHODS





Primary Endpoint:

Placebo-adjusted median percent change in triglycerides at Month 10

Multiplicity-controlled key secondary endpoints:

- Percent change from baseline at Months 10 and 12 (averaged) in fasting triglycerides
- . Percent change from baseline at Month 10 in fasting APOC3
- Percent change from baseline at Month 12 in fasting APOC3
- Incidence of positively adjudicated events of acute pancreatitis during the randomized period

PALISADE Enrolled Patients with FCS Defined Clinically or Genetically Confirmed

- Criteria included history of multiple TG measurements above 1000 mg/dL, despite best standard of care; plus at least one of the following:
- . Prior genetic testing diagnostic of FCS* OR
- 2. Recurrent episodes of acute pancreatitis[§] <u>OR</u>
- 3. Recurrent hospitalizations for severe abdominal pain without other explainable cause <u>OR</u>
- 4. History of childhood pancreatitis <u>OR</u>
- 5. Family history of HTG-induced acute pancreatitis

Genetic testing was done on all patients not previously tested for FCS variants

*Supportive genetic testing includes but is not limited to homozygous, compound heterozygous, or double heterozygote for loss-of-function or otherwise inactivating mutations in genes affecting lipoprotein lipase activity including LPL, APOC2, APOA5, GPIHBP1, GPD1, or LMF1; or evidence of low LPL activity (< 20% of normal) based on source-verifiable documentation. §Not caused by alcohol or cholelithiasis

REFERENCES

 Brunzell JD, Bierman EL. Med Clin North Am. 1982;66(2):455–6.
 Pallazola VA, et al. Eur J Prev Cardiol. 2020;27(19):2276-8.
 Warden BA, et al. J Clin Lipidol. 2020;14(2):201-6.
 Paquette M, et al. J Clin Endocrin Metab. 2021;106(9):e3473–e3482.
 Gelrud A, et al. Expert Rev Cardiovasc Ther. 2017;15(11): 879-887.
 Murphy MJ, et al. JAMA Intern Med. 2013;173(2):162–4. 7. Yuan G, Al-Shali KZ, Hegele RA. CMAJ. 2007;176(8):1113–20. 8. Nawaz H, et al. Am J Gastroenterol. 2015 Oct;110(10):1497-503. 9. Dron JS, Hegele RA. Front Endocrinol (Lausanne). 2020;11:455. 10. Hansen SEJ, et al. Clin Gastro Hep. 2021;19(8):1652-1660.e6. 11. Van Zwol W, et al. J Clin Med. 2019; 8:1085. 12. Ballantyne CM, et al. New Engl J Med. 2024; Published online: May 28, 2024. DOI: 10.1056/NEJMoa2404143. **Circulation** https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.072860.

ABBREVIATIONS

APOC3, apolipoprotein C3; AP, acute pancreatitis; BL, baseline; BMI, body mass index; CI, confidence interval; CMH, Cochran-Mantel-Haenszel; EOS, end of study; FCS, familial chylomicronemia syndrome; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HL, hepatic lipase; HTG, hypertriglyceridemia; LPL, lipoprotein lipase; MCS, Multifactorial Chylomicronemia Syndrome; N, number; Q, quartile; Q1, 1st quartile; Q3, 3rd quartile; SAE, serious adverse event; SD, standard deviation; SEM, standard error of mean; TEAE, treatment emergent adverse event; TG, triglycerides; TRL, triglyceride rich lipoproteins; VLDL-C, very low-density lipoprotein cholesterol; W, week.

DISCLOSURES AND ACKNOWLEDGEMENTS

E Goldberg is an employee of Arrowhead Pharmaceuticals Inc.

arrowhead


The study sponsors would like to thank the patients who participated and their families, and all investigators and staff who completed the trial




RESULTS

Table 1. PALISADE Baseline Characteristics

Pooled	Plozasiran	
Placebo (N=25)	25 mg (N=26)	50 mg (N=24)
47 (14)	48 (14)	43 (11)
11 (44)	14 (54)	13 (54)
14 (56)	12 (46)	11 (46)
19 (76)	19 (73)	17 (71)
25 (4)	26 (4)	25 (5)
39 (29, 50)	39 (27, 44)	30 (18, 37)
40 (18)	39 (17)	33 (20)
2053 (1435, 2755)	2008 (1204, 3361)	1902 (1434, 2948)
2272 (1141)	2350 (1375)	2492 (1523)
11 (44)	11 (42)	12 (50)
16 (64)	19 (73)	15 (63)
6 (24)	9 (35)	7 (29)
11 (44)	10 (39)	7 (29)
14 (56)	14 (54)	16 (67)
22 (88)	23 (89)	22 (92)
	(N=25) 47 (14) 11 (44) 13 (56) 19 (76) 25 (4) 39 (29, 50) 40 (18) 30 (18) 2272 (1141) 2272 (1141) 11 (44) 16 (64) 13 (64) 14 (56)	Pooled (N=25) 25 mg (N=26) 47 (14) 48 (14) 11 (44) 14 (54) 14 (56) 12 (46) 19 (76) 19 (73) 25 (4) 26 (4) 39 (29, 50) 39 (27, 44) 40 (18) 39 (17) 40 (18) 2008 (1435, 2755) 2053 (1435, 2755) 2008 (1204, 3361) 2272 (1141) 2350 (1375) 11 (44) 11 (42) 16 (64) 19 (73) 6 (24) 9 (35) 11 (44) 10 (39) 14 (56) 14 (54)







Study Month

75% of patients reached triglycerides < 880 mg/dL


and 50% reached < 500 mg/dL at 10 months

Figure 2. Plozasiran TG and APOC3 Responses Persisted Over 12 Months with No Significant Difference by FCS Genotype










American Pancreatic Association of Pancreatology (APA/JPS/CAP/IAP) 2024 | December 9–12, 2024 | Maui, Hawaii



Plozasiran 25 mg

*P<0.0001; †P<0.05. With Plozasiran vs Placebo

Figure 5. Plozasiran Significantly Reduced the Incidence of Acute Pancreatitis[†]




Table 2. Summary of Adverse Events

-	Pooled Placebo (N=25)	Plozasiran	
		25 mg (N=26)	50 mg (N=24)
Patients with Any TEAEs	20	23	20
Most Common TEAEs, N (?	%)		
Abdominal pain	5 (20)	7 (27)	6 (25)
COVID-19 infection*	0 (0)	5 (19)	7 (29)
Nasopharyngitis	3 (12)	5 (19)	2 (8)
Headache	2 (8)	3 (12)	5 (21)
Nausea	2 (8)	4 (15)	3 (13)
Back pain	2 (8)	3 (12)	2 (8)
Upper respiratory tract infection	2 (8)	3 (12)	2 (8)
Diarrhea	2 (8)	1 (4)	4 (17)
Severe TEAEs	5 (20)	3 (12)	3 (13)
Serious TEAEs	7 (28)	5 (19)	2 (8)
Deaths	0 (0)	0 (0)	0 (0)
Premature Discontinuations	6 (24)	3 (12)	2 (8)
HbA1c, mean (SD)			
Baseline	· · ·	5.7 (0.90)	
Month 12	• •	5.98 (1.00)	5.83 (1.56
Platelet Count, 10 ⁹ /liter, N			
Baseline	217.9 (80.5)	204.4 (70.4)	192.9 (50.7
Change from BL at Month 10	25.9 (38.2)	28.7 (61.2)	-4.4 (48.2
Change from BL at Month 12	8.6 (47.5)	-4.3 (40.8)	-8.7 (50.8
A greater proportion of experienced SAEs	placebo-tre	ated patien	its
Fewer premature discon with plozasiran	itinuations fr	om blinded	therapy
No reductions in platele	t counts		
Hyperglycemia with ploz		ned to patie	ents with
pre-diabetes and diabe			

pre-alabeles and alabeles No deaths

*The observed difference in COVID-19 occurrence in this trial was not seen in the larger phase 2b trials in mixed hyperlipidemia and severe hypertriglyceridemia also conducted during the COVID-19 pandemic, and likely was a chance finding.

Responses Were Similar by FCS Genotype

CONCLUSIONS

PALISADE met all alpha-controlled trial endpoints

Plozasiran (quarterly dosing) significantly reduced acute pancreatitis

LDL-Cholesterol

Study Month

Study Month

ApoB-100

- Plozasiran substantially reduced triglycerides in patients with persistent chylomicronemia (FCS or FCS-like syndrome*) and over half achieved TG treatment goals (75% < 880 mg/dL, 50% < 500 mg/dL), invariant of FCS genotype
- Reductions in TGs and APOC3 were apparent at 1 month and sustained thereafter over 12 months with comparable efficacy in genetically and clinicallydefined patients
- Reductions in atherogenic TRLs and minor increase in LDL-C with no change in ApoB
- Favorable safety and tolerability comparable to placebo
- Plozasiran is a novel therapeutic candidate for reducing plasma TG levels and risk of acute pancreatitis in patients with persistent chylomicronemia

*High risk MCS (patients with prior acute pancreatitis events and exceptionally high TGs).